Class, Biotech Co. Propose $10.65M Deal To End Merger Suit
By Jeff Montgomery ( October 27, 2022, 9:09 PM EDT) -- Former Asterias Biotherapeutics stockholders have reached a $10.65 million deal to settle a 3-year-old Delaware Chancery Court class action challenging the company's November 2018 stock-for-stock merger agreement with allegedly controlling investor BioTime Inc....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.